PF-06823859の新興薬剤に関する洞察と市場予測：2032年

PF-06823859はヒト化免疫グロブリンG1抗体で、IFNBに結合し、IFNARを介したシグナル伝達を阻害します。現在、2つの第II相臨床試験（NCT05192200、NCT03181893）が進行中であり、募集は行っていません。

今後数年間で、皮膚筋炎の市場シナリオは、世界中の広範な調査と医療支出の増加により変化します。各社は、病状を治療／改善するための新規アプローチに焦点を当てた治療法を開発し、課題を評価し、PF-06823859の優位性に影響を与える可能性のある機会を模索しています。皮膚筋炎に対する他の新興製品がPF-06823859に厳しい市場競争を与えることが予想され、近い将来、後発の新興治療薬の発売が市場に大きな影響を与えると予測されています。思われます。

当レポートでは、主要7ヶ国におけるPF-06823859市場について調査し、市場の概要とともに、2027年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 皮膚筋炎に対するPF-06823859の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（後期段階の新興治療法）

第4章 PF-06823859市場評価

• 皮膚筋炎に対するPF-06823859の市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国における皮膚筋炎に対するPF-06823859の市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第5章 SWOT分析

第6章 アナリストの見解

第7章 付録

第8章 DelveInsightのサービス内容

第9章 免責事項

第10章 DelveInsightについて

第11章 レポート購入オプション

List of Tables

• Table 1: PF-06823859, Clinical Trial Description, 2023
• Table 2: PF-06823859, General Description
• Table 3: Competitive Landscape (Emerging Therapies)
• Table 4: PF-06823859 Market Size in the 7MM, in USD million (2019-2032)
• Table 5: PF-06823859 Market Size in the US, in USD million (2019-2032)
• Table 6: PF-06823859 Market Size in Germany, in USD million (2019-2032)
• Table 7: PF-06823859 Market Size in France, in USD million (2019-2032)
• Table 8: PF-06823859 Market Size in Italy, in USD million (2019-2032)
• Table 9: PF-06823859 Market Size in Spain, in USD million (2019-2032)
• Table 10: PF-06823859 Market Size in the UK, in USD million (2019-2032)
• Table 11: PF-06823859 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: PF-06823859 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: PF-06823859 Market Size in the United States, USD million (2019-2032)
• Figure 3: PF-06823859 Market Size in Germany, USD million (2019-2032)
• Figure 4: PF-06823859 Market Size in France, USD million (2019-2032)
• Figure 5: PF-06823859 Market Size in Italy, USD million (2019-2032)
• Figure 6: PF-06823859 Market Size in Spain, USD million (2019-2032)
• Figure 7: PF-06823859 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: PF-06823859 Market Size in Japan, USD million (2019-2032)

“"PF-06823859 Emerging Drug Insight and Market Forecast - 2032" ” report provides comprehensive insights about PF-06823859 for dermatomyositis in the seven major markets. A detailed picture of the PF-06823859 for dermatomyositis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the PF-06823859 for dermatomyositis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the PF-06823859 market forecast analysis for dermatomyositis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in dermatomyositis.

Drug Summary:

PF-06823859 is a humanized immunoglobulin G1 antibody, which binds to IFNB, inhibiting signaling via IFNAR.

Currently, the drug is in two Phase II clinical trials (NCT05192200, NCT03181893) and is active, not recruiting.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the PF-06823859 description, mechanism of action, dosage and administration, research and development activities in dermatomyositis.
• Elaborated details on PF-06823859 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the PF-06823859 research and development activities in dermatomyositis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around PF-06823859.
• The report contains forecasted sales of PF-06823859 for dermatomyositis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for dermatomyositis.
• The report also features the SWOT analysis with analyst views for PF-06823859 in dermatomyositis.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

PF-06823859 Analytical Perspective by DelveInsight

In-depth PF-06823859 Market Assessment

This report provides a detailed market assessment of PF-06823859 for dermatomyositis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

PF-06823859 Clinical Assessment

The report provides the clinical trials information of PF-06823859 for dermatomyositis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for dermatomyositis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence PF-06823859 dominance.
• Other emerging products for dermatomyositis are expected to give tough market competition to PF-06823859 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of PF-06823859 in dermatomyositis.
• Our in-depth analysis of the forecasted sales data of PF-06823859 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the PF-06823859 in dermatomyositis.

Key Questions:

• What is the product type, route of administration and mechanism of action of PF-06823859?
• What is the clinical trial status of the study related to PF-06823859 in dermatomyositis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the PF-06823859 development?
• What are the key designations that have been granted to PF-06823859 for dermatomyositis?
• What is the forecasted market scenario of PF-06823859 for dermatomyositis?
• What are the forecasted sales of PF-06823859 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to PF-06823859 for dermatomyositis?
• Which are the late-stage emerging therapies under development for the treatment of dermatomyositis?

Table of Contents

1. Report Introduction

2. PF-06823859 Overview in Dermatomyositis

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Late-stage Emerging Therapies)

4. PF-06823859 Market Assessment

• 4.1. Market Outlook of PF-06823859 in dermatomyositis
• 4.2. 7MM Analysis
  • 4.2.1. Market Size of PF-06823859 in the 7MM for dermatomyositis
• 4.3. Country-wise Market Analysis
  • 4.3.1. Market Size of PF-06823859 in the United States for dermatomyositis
  • 4.3.2. Market Size of PF-06823859 in Germany for dermatomyositis
  • 4.3.3. Market Size of PF-06823859 in France for dermatomyositis
  • 4.3.4. Market Size of PF-06823859 in Italy for dermatomyositis
  • 4.3.5. Market Size of PF-06823859 in Spain for dermatomyositis
  • 4.3.6. Market Size of PF-06823859 in the United Kingdom for dermatomyositis
  • 4.3.7. Market Size of PF-06823859 in Japan for dermatomyositis

5. SWOT Analysis

6. Analysts' Views

7. Appendix

• 7.1. Bibliography
• 7.2. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

11. Report Purchase Options